Our platforms: proprietary assays & medicinal chemistry

The competitive position of Senexis relies on the barriers to entry provided by its intellectual property rights and know-how in the areas of amyloid biochemistry, assay development, medicinal chemistry, amyloid pathology and clinical development.  In particular, the broad and defensible portfolio of “composition-of-matter” patents protects a series of compounds that inhibit the misfolding, aggregation and associated toxicity of amyloid-forming proteins. The portfolio of compounds comprises novel molecules generated by the Company’s proprietary assay platforms and discovery tools, along with in-licensed compounds that Senexis has continued to develop further. This approach provides multiple product opportunities for potentially treating all diseases of amyloid-related toxicity derived from an efficient and cost-effective discovery platform.

Senexis operates on a “semi-virtual” basis, in which only the proprietary core in vitro assays are run internally.  The Company has been established in a self-contained small operational base of 1,300 square feet in the Bioincubator Building on the Babraham Research Campus in Cambridge since June 2004.

The Company's registered office is located at Babraham Hall on the Campus, a photograph of which is shown to the right.